Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $37 to $38.
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $37 to $38.
Related Posts
Susquehanna Maintains Positive on Norwegian Cruise Line, Lowers Price Target to $15
Susquehanna analyst Christopher Stathoulopoulos maintains Norwegian Cruise Line (NYSE:NCLH) with a Positive and lowers the price target from $20 to $15.
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today’s pre-market trading as the company reported better-than-expected first-quarter financial…
Drug Shortages in Focus: How FDA’s Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March.
Methotrexate is an injected medication utilized to treat various cancers and autoimmune diseases like rheumatoid arthritis, as stated by the National Cancer Institute.